| Dr Tawa M Witko, PSYD | |
|
701 E 6th St, Mclaughlin Clinic, Mclaughlin, SD 57642 | |
| (605) 823-4458 | |
| (605) 823-4459 |
| Full Name | Dr Tawa M Witko |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 701 E 6th St, Mclaughlin, South Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144380866 | NPI | - | NPPES |
| 246779 | Other | AETNA | |
| 246779 | Other | MIDLANDS CHOICE | |
| 456 | Other | DAKOTA CARE | |
| DB3096 | Other | UNITED HEALTHCARE | |
| 14283 | Other | AVERA HEALTH PLAN | |
| 6552242 | Medicaid | SD | |
| 246779 | Other | CIGNA | |
| 4994787 | Other | BLUE CROSS | |
| 10025457300 | Other | NEBRASKA MEDICAID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 456 (South Dakota) | Primary |
| Entity Name | Fort Yates Indian Health Service Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609851039 PECOS PAC ID: 3678462744 Enrollment ID: O20040315001479 |
News Archive
In this post on the PLoS "Speaking of Medicine" blog, Madhukar Pai, a professor and tuberculosis (TB) researcher based at McGill University, co-chair of the Stop TB Partnership's New Diagnostics Working Group, and a consultant to the Bill & Melinda Gates Foundation, describes a recent conference on TB diagnostics at St. John's Research Institute in Bangalore, India, that aimed "to stimulate industry interest and investments in TB innovations."
Virginia Women's Center has been selected to participate in a nationwide clinical trial, one that will ultimately hope to prevent the human papillomavirus virus (HPV) from progressing into cervical cancer and treat women who have HPV and the precancerous lesions associated with it. The Richmond-area OB-GYN practice has participated in over 50 clinical research studies since 1997, all of which have contributed to the future of safe and effective medicine for women.
Reporting for Kaiser Health News and USA Today, KHN staff writer Christopher Weaver reports: "The White House unveiled details last week of a $5 billion program to provide financial relief to companies that offer health coverage to early retirees.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
A new study sheds light-both literally and figuratively-on the intricate brain cell connections responsible for anxiety.
› Verified 4 days ago
| Entity Name | Fort Yates Indian Health Service |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710037288 PECOS PAC ID: 9032287008 Enrollment ID: O20090116000441 |
News Archive
In this post on the PLoS "Speaking of Medicine" blog, Madhukar Pai, a professor and tuberculosis (TB) researcher based at McGill University, co-chair of the Stop TB Partnership's New Diagnostics Working Group, and a consultant to the Bill & Melinda Gates Foundation, describes a recent conference on TB diagnostics at St. John's Research Institute in Bangalore, India, that aimed "to stimulate industry interest and investments in TB innovations."
Virginia Women's Center has been selected to participate in a nationwide clinical trial, one that will ultimately hope to prevent the human papillomavirus virus (HPV) from progressing into cervical cancer and treat women who have HPV and the precancerous lesions associated with it. The Richmond-area OB-GYN practice has participated in over 50 clinical research studies since 1997, all of which have contributed to the future of safe and effective medicine for women.
Reporting for Kaiser Health News and USA Today, KHN staff writer Christopher Weaver reports: "The White House unveiled details last week of a $5 billion program to provide financial relief to companies that offer health coverage to early retirees.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
A new study sheds light-both literally and figuratively-on the intricate brain cell connections responsible for anxiety.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tawa M Witko, PSYD Po Box 879, Mclaughlin Clinic, Mc Laughlin, SD 57642-0879 Ph: (605) 823-4458 | Dr Tawa M Witko, PSYD 701 E 6th St, Mclaughlin Clinic, Mclaughlin, SD 57642 Ph: (605) 823-4458 |
News Archive
In this post on the PLoS "Speaking of Medicine" blog, Madhukar Pai, a professor and tuberculosis (TB) researcher based at McGill University, co-chair of the Stop TB Partnership's New Diagnostics Working Group, and a consultant to the Bill & Melinda Gates Foundation, describes a recent conference on TB diagnostics at St. John's Research Institute in Bangalore, India, that aimed "to stimulate industry interest and investments in TB innovations."
Virginia Women's Center has been selected to participate in a nationwide clinical trial, one that will ultimately hope to prevent the human papillomavirus virus (HPV) from progressing into cervical cancer and treat women who have HPV and the precancerous lesions associated with it. The Richmond-area OB-GYN practice has participated in over 50 clinical research studies since 1997, all of which have contributed to the future of safe and effective medicine for women.
Reporting for Kaiser Health News and USA Today, KHN staff writer Christopher Weaver reports: "The White House unveiled details last week of a $5 billion program to provide financial relief to companies that offer health coverage to early retirees.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
A new study sheds light-both literally and figuratively-on the intricate brain cell connections responsible for anxiety.
› Verified 4 days ago